The Cancer Letter Archives
The Cancer Letter was founded in 1973, two years after Congress passed the National Cancer Act of 1971. These archives represent the first 40 years of The Cancer Letter, which is published weekly.
CCL
Vol.
35
No.
1
January 27, 2012
- Regorafenib Trial Meets Primary Endpoint; Overall Survival Improved by 29 Percent
- Tesetaxel Showed 20 Percent Response In Second-Line Therapy In Phase IIb Trial
- ETP-ALL May Be Linked To Acute Myeloid Leukemia
- CyberKnife Delivers 100 Percent PFS at 18.3 Month Followup
- BRCA1 and BRCA2 Mutations Linked To Higher Survival
- Matted Lymph Nodes Can Predict Survival Rate, Spread of Disease
- Chromosomal Abnormalities Predict Long Median Survival
- Analysis Shows No Mortality Benefit From Regular PSA Screening
- Ovarian Cancer Symptom Indices May Need to be Re-Evaluated
- Self-Collected Pap Smear Tests Could Advance HPV Screening
- Trials Approved by NCI CTEP For the Month of January
- Palmetto Establishes Coverage For Thyroid Genomic Test
- FDA Approves Inlyta Pill For Renal Cell Carcinoma
